109229-22-3

Basic information

• Product Name: 6-benzyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one
• Synonyms: 6-benzyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one;6-Benzyl-5,6,7,8-tetrahydro-3H-pyrido[4,3-d]pyrimidin-4-one;3-d]pyriMidin-4(3H)-one;6-benzyl-5;6-benzyl-3H,4H,5H,6H,7H,8H-pyrido[4,3-d]pyriMidin-4-one;6-Benzyl-5,6,7,8-tetrahydro-1H-pyrido[4,3-d]pyriMidin-4-one;Benzyl-5,6,7,8-tetrahydropyrido[4,3-d]pyriMidin-4(3H)-one;6-Benzyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)
• CAS NO: 109229-22-3
• Molecular Formula: C₁₄H₁₅N₃O
• Molecular Weight: 241.29
• Product Categories: CHIRAL CHEMICALS
• Mol File: 109229-22-3.mol

Chemical Properties

• Melting Point: 165-166.5 °C(Solv: acetone (67-64-1))
• Boiling Point: 406.5±55.0 °C(Predicted)
• Appearance: /
• Density: 1.27 g/cm³
• Refractive Index: 1.662
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 6.65±0.20(Predicted)
• CAS DataBase Reference: 6-benzyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-benzyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one(109229-22-3)
• EPA Substance Registry System: 6-benzyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one(109229-22-3)

Safety Data

• Hazardous Substances Data: 109229-22-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-Benzyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one is used as a key intermediate in the discovery and optimization of quinazolinones. These quinazolinones are being investigated as new P2X3 receptor antagonists, which have potential therapeutic applications in treating various conditions such as chronic cough, pain, and inflammatory disorders.
The compound's unique structure allows for the development of novel P2X3 receptor antagonists with improved potency, selectivity, and pharmacokinetic properties. By targeting the P2X3 receptor, these quinazolinones can modulate the body's response to pain and inflammation, offering a promising avenue for the development of new therapeutic agents.

InChI:InChI=1/C14H15N3O/c18-14-12-9-17(7-6-13(12)15-10-16-14)8-11-4-2-1-3-5-11/h1-5,10H,6-9H2,(H,15,16,18)

Upstream product

• 41276-30-6 C₉H₁₄O₃NC₆H₅ 
• 6313-33-3 formamidine hydrochloride 
• 159660-85-2 1-benzyl-4-aminotetrahydropyridine-3-carboxylic acid methyl ester 
• 463-52-5 formamidine 
• 3473-63-0 formamidine acetic acid 
• 1454-53-1 ethyl 1-benzyl-4-oxopiperidine-3-carboxylate hydrochloride 
• 67848-59-3 4-piperidone-3-carboxylic acid ethyl ester 
• 618-32-6 Benzoyl bromide 

Downstream Products

• 1430100-84-7 6-[3-(1,3-benzothiazol-2-yl)propanoyl]-4-(4-fluorobenzyl)-5,6,7,8-tetrahydropyrido-[4,3-d]pyrimidine 
• 1430101-38-4 6-benzyl-4-bromo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine 
• 1430101-39-5 6-benzyl-4-(4-fluorobenzyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine 
• 1071436-29-7 (S)-2-[6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-2-(4-trifluoromethyl-phenyl)-ethanol 
• 1071436-10-6 (R)-2-[6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-2-phenyl-ethanol 
• 1071436-17-3 [(R)-1-(4-chloro-phenyl)-ethyl]-[6-(5-chloro-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yl]-amine 
• 1071436-05-9 [6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yl]-((R)-1-p-tolyl-ethyl)-amine 
• 1071436-20-8 (R)-N-(1-(4-chlorophenyl)ethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-amine 
• 1071436-19-5 (R)-6-benzyl-N-(1-(4-chlorophenyl)ethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-amine 
• 944902-70-9 4-methoxy-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidine 
• 1071435-57-8 6-benzyl-4-methoxy-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine 
• 1332455-21-6 tert-butyl 2-[6-(biphenyl-4-ylcarbonyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl]-2,7-diazaspiro[4.5]nonane-7-carboxylate 
• 1332455-30-7 ethyl 1-(6-(4-chlorophenylsulfonyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)piperidine-4-carboxylate 
• 1332455-29-4 biphenyl-4-yl{4-[4-(3-ethyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl}methanone 

Relevant articles and documents

New P2X3 receptor antagonists. Part 2: Identification and SAR of quinazolinones

Numerous potent P2X3 antagonists have been discovered and the therapeutic potential of P2X3 antagonism already comprises proof-of-concept data obtained in clinical trials with the most advanced compound. We have lately reported the discovery and optimization of thia-triaza-tricycle compounds with potent P2X3 antagonistic properties. This Letter describes the SAR of a back-up series containing a 4-oxo-quinazoline central ring. The discovery of the highly potent compounds 51 is presented.

TETRAHYDROPYRIDO[4,3-D]PYRIMIDINE INHIBITORS OF ATR KINASE

The present invention relates to tetrahydropyrido[4,3-d]pyrimidine based compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.

New tetrahydropyrido pyrimidinecarboxylic compound or salt thereof

To provide a compound having an inhibitory activity for an androgen receptor. A tetrahydropyridopyrimidine compound represented by the following general formula (I) or a pharmaceutically acceptable thereof (in the formula, X and R are as defined in the specification).

Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention That Are Efficacious in Models of Wet Age-Related Macular Degeneration

The benefit of intravitreal anti-VEGF therapy in treating wet age-related macular degeneration (AMD) is well established. Identification of VEGFR-2 inhibitors with optimal ADME properties for an ocular indication provides opportunities for dosing routes beyond intravitreal injection. We employed a high-throughput in vivo screening strategy with rodent models of choroidal neovascularization and iterative compound design to identify VEGFR-2 inhibitors with potential to benefit wet AMD patients. These compounds demonstrate preferential ocular tissue distribution and efficacy after oral administration while minimizing systemic exposure.

PYRIMIDINE AND PYRIDINE DERIVATIVES USEFUL IN THERAPY

The invention provides compounds of formula (I), wherein one of X, Y and Z represents N and the other two represent CH, or X=Y-Z represents N=CH-N; W represents a CI-6 alkylene group which may be straight or branched; R1 represents H, phenyl, naphthyl, heteroaryl1, heterocyclyl1 or C3-6 cycloalkyl; wherein each phenyl, naphthyl, heteroaryl', heterocyclyl1 and C3-6 cycloalkyl group is optionally substituted, and wherein each phenyl, naphthyl, heteroaryl1, heterocyclyl1 and C3-6 cycloalkyl group is optionally fused to a 5- or 6-membered heteroaromatic or heterocyclic ring containing from 1 to 3 heteroatoms (selected from N, O and S); and each heteroaryl1, heterocyclyl1 and C3-6 cycloalkyl group is optionally fused to a benzene ring; m is 1 or 2; n is 0, 1 or 2; A is C=O or SO2; V represents a bond or C1-8 alkylene which may be straight or branched; R2 represents H, -S-(C1-6 alkyl), -SO2N(C1-6 alkyl)2, -CO2-(C1-6 alkyl), - NHCOCH2-phenyl, -OCH2- phenyl, -S02-phenyl, -NR3R4, phenyl, naphthyl, heteroaryl2, heterocyclyl2, -CO-heterocyclyl2 or C3-6 cycloalkyl; wherein each phenyl, naphthyl, heteroaryl2, heterocyclyl2 and C3-6 cycloalkyl group is optionally substituted, and wherein each phenyl, naphthyl, heteroaryl2, heterocyclyl2 and C3-6 cycloalkyl group is optionally fused to a 5- or 6-membered heteroaromatic or heterocyclic ring containing from 1 to 3 heteroatoms (selected from N, O and S); and wherein each heteroaryl2, heterocyclyl2 and C3-6 cycloalkyl group is optionally fused to a benzene ring; and pharmaceutically acceptable salts and solvates thereof. The compounds are useful as pharmaceuticals, particularly in the treatment of fibrotic diseases, cancer and pain.

TASK CHANNEL ANTAGONISTS

This invention relates to TASK-1 and/or TASK-3 antagonists and/or their pharmaceutically acceptable salts, compositions and methods for treating and preventing disorders which are caused by activation or by an activated TASK-1 and/or TASK-3, and disorders

TASK CHANNEL ANTAGONISTS

This invention relates to TASK-1 and/or TASK-3 antagonists and/or their pharmaceutically acceptable salts, compositions and methods for treating and preventing disorders which are caused by activation or by an activated TASK-1 and/or TASK-3, and disorders

2-Cyanophenyl fused heterocyclic compounds, and compositions and uses thereof

Fused heterocyclic compounds are provided according to formula 1: where R1, R2, R3, and m are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.

PYRID-2-YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF

Fused heterocyclic compounds are provided according to formula 1a or 1b: where R1, R2, and R3 are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.

Development and experimental validation of a docking strategy for the generation of kinase-targeted libraries

A high-throughput docking strategy for the filtering of in silico compounds and the generation of kinase-targeted libraries is described. Systematic docking and scoring in three kinase crystal 3D structures of 123 structurally diverse kinase ligands led to the determination of six thresholds for each kinase. These thresholds were used as filters for the virtual screening of two collections of compounds: a collection of more than 2500 drugs and drug-like compounds (negative control) and a kinase-targeted library of 1440 compounds. This strategy was then experimentally validated by testing 60 compounds from the kinase-targeted library on 41 kinases from five different families. The 60 compounds were split into those passing all the thresholds and the others (30 compounds in each group). The overall hit enrichment was 6.70-fold higher in the first group, validating our approach for the generation of kinase-targeted libraries and the identification of scaffolds with high kinase inhibitory potential.